MAPK (ATF2, c-Jun, c-Myc, MEF2, STAT1alpha) Transcription Factor Assay Kit (Colorimetric) (ab207212)

Overview

  • Product name

    MAPK (ATF2, c-Jun, c-Myc, MEF2, STAT1alpha) Transcription Factor Assay Kit (Colorimetric)
  • Detection method

    Colorimetric
  • Sample type

    Nuclear Extracts
  • Assay type

    Semi-quantitative
  • Sensitivity

    500 ng/well
  • Assay time

    3h 30m
  • Species reactivity

    Reacts with: Mouse, Human
  • Product overview

    MAPK (ATF2, c-Jun, c-Myc, MEF2, STAT1alpha) Transcription Factor Assay Kit (Colorimetric) (ab207212) is a high throughput assay to quantify activation of MAPK regulated transcription factors. This assay combines a quick ELISA format with a sensitive and specific non-radioactive assay for transcription factor activation.


    A specific double stranded DNA sequence containing the MAPK consensus binding site has been immobilized onto a 96-well plate. Active MAPK present in the nuclear extract specifically binds to the oligonucleotide. MAPK is detected by a primary antibody that recognizes an epitope of MAPK accessible only when the protein is activated and bound to its target DNA. An HRP-conjugated secondary antibody provides sensitive colorimetric readout at OD 450 nm. This product detects only human MAPK.


    Key performance and benefits:



    • Assay time: 3.5 hours (cell extracts preparation not included).

    • Detection limit: < 0.5 µg nuclear extract/well.

    • Detection range: 0.5 – 5 µg of nuclear extract/well for c-Myc, MEF2 and STAT1; 1 – 10 µg nuclear extract/well for ATF-2 and c-Jun.

  • Notes

    The transmission of extracellular signals into intracellular responses is a complex process that often involves the activity of mitogen-activated protein kinases (MAPKs). The MAPK pathway is a three kinase cascade consisting of a MAPK kinase (MAPKKK or MEKK) that activates a MAP/ERK kinase (MEK or MAPKK). This stimulates a phosphorylation-dependent increase in the activity of the MAP kinase. Upon activation, MAPKs phosphorylate a variety of intracellular targets including transcription factors, transcription adaptor proteins, membrane and cytoplasmic substrates as well as other protein kinases.

    At least three parallel MAPK pathways exist in humans. The extracellular signal-regulated protein kinase (ERK) pathway primarily transmits mitogenic and differentiation stimuli, while the c-Jun N-terminal kinase (JNK) and p38 pathways predominantly transmit stress and cytokine stimuli. c-Myc, an ERK substrate, is a transcription factor that regulates cell growth and differentiation, glycolysis and apoptosis. Deregulation of c-Myc has been implicated in the origin of diverse human cancers. Elk-1 is a member of the ternary complex factor (TCF) sub-family of the ETS domain family. Elk-1 can be stimulated by all three MAPK pathways, and its main function is the regulation of the activity of the c-Fos promoter in response to extracellular stimuli. MEF2, a member of the MADS box family, is mainly involved in muscle differentiation, but also plays roles in muscle hypertrophy, neuronal survival and T-cell apoptosis. MEF2 is activated by both the p38 and ERK5 pathways.1 STAT1 is involved in activation of IFNα and γ genes, and is activated by p38 and JNK pathways. c-Jun is a member of the activator protein-1 (AP-1) family and is activated by both ERK1/2 and JNK pathways.2 AP-1 members play roles in the expression of genes involved in proliferation and cell cycle progression. ATF-2 is a member of the ATF/CREB family that binds to the cAMP response element (CRE). ATF-2 is activated by ERK1/2, JNK and p38.

  • Platform

    Microplate reader

Properties

  • Storage instructions

    Please refer to protocols.
  • Components 2 x 96 tests
    10X Antibody Binding Buffer 2 x 2.2ml
    10X Wash Buffer 1 x 60ml
    96-well MAPK assay plate 2 units
    Anti-mouse HRP-conjugated IgG 1 x 11µl
    Anti-rabbit HRP-conjugated IgG (0.25 μg/μL) 2 x 11µl
    AP-1 Mutated oligonucleotide (10 pmol/μL) 1 x 100µl
    AP-1 Wild-type oligonucleotide (10 pmol/μL) 1 x 100µl
    ATF-2 Mutated oligonucleotide (10 pmol/µL) 1 x 100µl
    ATF-2 Wild-type oligonucleotide (10 pmol/µL) 1 x 100µl
    Binding Buffer 1 x 10ml
    c-Myc antibody 1 x 11µl
    c-Myc Mutated oligonucleotide (10 pmol/μL) 1 x 100µl
    c-Myc Wild-type oligonucleotide (10 pmol/μL) 1 x 100µl
    Developing Solution 2 x 11ml
    Dithiothreitol (DTT) (1 M) 1 x 100µl
    K-562(TPA) nuclear extract (2.5µg/μL) 1 x 40µl
    Lysis Buffer 1 x 10ml
    MEF2 antibody 1 x 11µl
    MEF2 mutated oligonucleotide (10 pmol/μL) 1 x 100µl
    MEF2 wild-type oligonucleotide (10 pmol/μL) 1 x 100µl
    Phospho-c-Jun antibody 1 x 22µl
    Phosphorylated ATF-2 antibody 1 x 11µl
    Plate sealer 2 units
    Protease Inhibitor Cocktail 1 x 100µl
    STAT mutated oligonucleotide (10 pmol/μL) 1 x 100µl
    STAT Wild-type oligonucleotide (10 pmol/µL) 1 x 100µl
    STAT1α antibody 1 x 11µl
    Stop Solution 1 x 60ml
  • Research areas

  • Relevance

    MAPK is activated by phosphorylation, whereupon the protein translocates to the nucleus, where it phosphorylates nuclear targets. MAPK is an important integration point of many signalling pathways, for a range of cellular processes including proliferation, differentiation, transcription regulation and development.
  • Alternative names

    • ERK1
    • ERT2
    • Extracellular signal regulated kinase 1
    • Insulin stimulated MAP2 kinase
    • MAP kinase 1
    • Microtubule associated protein 2 kinase
    • mitogen-activated protein kinase 3
    • P44ERK1
    • P44MAPK
    • PRKM3
    see all
  • Database links

Images

  • Nuclear extracts from various cell lines were tested for ATF2, c-Myc, c-Jun, STAT1 and MEF2 activation. Cell lines used were HeLa (anisomycin-treated) for ATF2, Jurkat (1 day growth) for c-Myc, K-562 (TPA-treated) for c- Jun, U-937 (TPA + IFNγ treated) for STAT1 and C2C12 for MEF2. Activation was also monitored in the absence (grey) and in the presence of wild-type (black) or mutated (white) consensus binding oligonucleotides. Note that the wild-type oligonucleotide reduces binding of the transcription factors by over 90%, while incubation with the mutant MAPK competitor oligos have limited effect on DNA binding. These results are provided for demonstration purposes only.

Protocols

References

ab207212 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab207212.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up